Potential role for microRNA-16 (miR-16) and microRNA-93 (miR-93) in diagnosis and prediction of disease progression in mycosis fungoides in Egyptian patients

Talaat, Iman M.; Abdelmaksoud, Rania; Guimei, Maha; Agamia, Naglaa; Nugud, Ahmed; El‐Serafi, Ahmed T.

doi:10.1371/journal.pone.0224305

Cited by 8 publications

(8 citation statements)

References 41 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumor suppressor gene PTEN is a known target of the miR-93–5p and miR-181 families ( 61 , 62 ). However, contrary to the findings of previous studies, a recent study on miR-93 found that the expression of miR-93 was significantly downregulated in both early and advanced MF compared with normal and eczema cases ( 32 ). Therefore, further studies with larger cohorts of MF patients are needed to explore the role of miR-93 in the progression of MF.…”

Section: Mir and Mfcontrasting

confidence: 77%

“…Specifically, miR-93 not only plays a role in the pathogenesis of MF but can also be used as a specific biomarker for the diagnosis of MF. The significant downregulation of miR-93 can be used for the early diagnosis of early challenging cases ( 32 ).…”

Section: Mir and Mfmentioning

confidence: 99%

“…However, van Kester et al observed that miR-16 in tumoral MF was upregulated compared with inflammatory dermatosis (15). Similarly, additional evidence suggests that miR-16 was significantly upregulated in advanced MF compared with patients at early stage and could be used to predict aggressive clinical course (32). Thus, more studies are needed to explore the specific expression and biological function of miR-16 in MF.…”

Section: Mir and Cutaneous T-cell Lymphoma (Ctcl)mentioning

confidence: 99%

See 2 more Smart Citations

The Role of microRNA in Pathogenesis, Diagnosis, Different Variants, Treatment and Prognosis of Mycosis Fungoides

2021

View full text Add to dashboard Cite

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), accounting for approximately 50% of all CTCLs. Although various molecular changes in MF have been described in existing studies, no obvious disease-specific changes have been found thus far. microRNAs (miRs) are short, noncoding RNA molecules that play roles in the post-transcriptional regulation of oncogenes and tumor suppressor genes in various diseases. Recently, there has been rapidly expanding experimental evidence for the role of miRs in the progression, early diagnosis, prognosis prediction for MF. Efforts to improve early diagnosis and develop personalized therapy options have become more important in recent years. Here, we provide an overview and update of recent advances regarding miRs associated with MF. Furthermore, we provide insights into future opportunities for miR-based therapies.

show abstract

Section: Mir and Mfcontrasting

confidence: 77%

Section: Mir and Mfmentioning

confidence: 99%

Section: Mir and Cutaneous T-cell Lymphoma (Ctcl)mentioning

confidence: 99%

See 1 more Smart Citation

The Role of microRNA in Pathogenesis, Diagnosis, Different Variants, Treatment and Prognosis of Mycosis Fungoides

2021

View full text Add to dashboard Cite

show abstract

“…Talaat et al The expression of Bcl-2 in MF, eczema and control groups was investigated. Accordingly, while an intense Bcl-2 expression was observed in the stage-independent MF group, only basal keratinocytes Bcl-2 staining was observed in eczema and control groups (21).…”

Section: Discussionmentioning

confidence: 83%

Role of Mast Cell, Ki-67 and Bcl-2 in the Diagnosis of Mycosis Fungoides

DAYE,

FINDIK,

ISIK

et al. 2023

Preprint

View full text Add to dashboard Cite

Diagnosis of early-stage MF, there are molecular studies that include Bcl-2 and ki-67, but there is no study showing that mast cells can be used both in the diagnosis of early-stage MF and in the etiopathogenesis of MF. In our study, we aimed to show that Ki-67, Bcl-2 and mast cell staining, which can be easily obtained in every laboratory, are helpful markers in the diagnosis of early-stage MF. Methods: A total of 81 cases, including 27 Mycosis Fungoides, 27 benign inflammatory dermatoses (psoriasis, lichen planus, eczema) and 27 patients without any disease, were included in the study retrospectively. Ki-67, Bcl-2 and mast cell counts were made under a light microscope with stained slides. Results: Mast cells were found to be significantly higher in cases of mycosis fungoides compared to cases of benign inflammatory dermatosis (p>0.001). In mycosis fungoides cases, ki-67, Bcl-2 and mast cells were significantly higher compared to the control group (p>0.001). In benign inflammatory dermatosis cases, ki-67 and Bcl-2 were found to be significantly higher than the control group (p>0.001). Conclusion: MF lesions are initially included in the differential diagnosis of many diseases including eczema, psoriasis, and lichen planus. In this case, histopathological examination is used in order to reach a clear diagnosis. Ki-67, Bcl-2 and mast cells were found significantly higher in MF patients compared to the control group. However, no difference was found between MF and benign inflammatory dermatoses in ki-67 and Bcl-2 staining.

show abstract

“…Aberrant miRNA levels are common in CTCL. Many investigations have validated miRNA classifiers that can discriminate CTCL from benign inflammation ( 117 ) and predict disease progression ( 118 , 119 ) and prognosis in patients with CTCL ( 120 , 121 ). Many studies have shown that miRNAs are involved in many signaling pathways that regulate the cell cycle ( 122 ) and apoptosis resistance, particularly the Notch, STAT, and ( 123 ) NF κ B pathogenic pathways.…”

Section: Dna Methylation For Dysregulated Mirnas In Ctclmentioning

confidence: 99%

Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma

Zhang

2021

Front. Oncol.

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCLs) comprise a group of heterogeneous diseases involving malignant T cells. The pathogenesis and etiology of CTCL are still unclear, although a large number of genetic and epidemiological studies on CTCL have been conducted. Most CTCLs have an indolent course, making early diagnosis difficult. Once large-cell transformation occurs, CTCL progresses to more aggressive types, resulting in an overall survival of less than five years. Epigenetic drugs, which have shown certain curative effects, have been selected as third-line drugs in patients with relapsing and refractory CTCL. Many studies have also identified epigenetic biomarkers from tissues and peripheral blood of patients with CTCL and suggested that epigenetic changes play a role in malignant transformation and histone deacetylase inhibitor (HDACi) resistance in CTCL. Single-cell sequencing has been applied in CTCL studies, revealing heterogeneity in CTCL malignant T cells. The mechanisms of HDACi resistance have also been described, further facilitating the discovery of novel HDACi targets. Despite the heterogeneity of CTCL disease and its obscure pathogenesis, more epigenetic abnormalities have been gradually discovered recently, which not only enables us to understand CTCL disease further but also improves our understanding of the specific role of epigenetics in the pathogenesis and treatment. In this review, we discuss the recent discoveries concerning the pathological roles of epigenetics and epigenetic therapy in CTCL.

show abstract

Potential role for microRNA-16 (miR-16) and microRNA-93 (miR-93) in diagnosis and prediction of disease progression in mycosis fungoides in Egyptian patients

Cited by 8 publications

References 41 publications

The Role of microRNA in Pathogenesis, Diagnosis, Different Variants, Treatment and Prognosis of Mycosis Fungoides

The Role of microRNA in Pathogenesis, Diagnosis, Different Variants, Treatment and Prognosis of Mycosis Fungoides

Role of Mast Cell, Ki-67 and Bcl-2 in the Diagnosis of Mycosis Fungoides

Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma

Contact Info

Product

Resources

About